Ai Drug Repurposing Market Report: Market Size & Forecast 2026

The AI drug repurposing market encompasses software platforms, machine learning algorithms, and professional services designed to analyze existing drugs and identify new therapeutic indications. This approach, also known as computational drug repositioning, leverages vast biomedical datasets including clinical trial records, molecular databases, and scientific literature to uncover hidden patterns. By repurposing approved or late-stage drugs, pharmaceutical companies can bypass early safety trials and significantly reduce the time and cost of bringing treatments to market.

The high cost and long timelines associated with novel drug development, which can exceed $2 billion and take over a decade, have intensified interest in AI-powered repurposing strategies. Machine learning models can process millions of data points from scientific literature, clinical trials, and genomic databases to predict drug efficacy for new indications with greater speed than traditional methods.

The market is segmented by component into software and platform solutions, along with professional services including consulting and implementation support. Technology segmentation includes machine learning, deep learning, and natural language processing capabilities, while application areas span oncology, cardiovascular diseases, neurology, and rare disease treatments.

What are the recent trends and outlook?

Future growth will be shaped by advances in generative AI and large language models capable of integrating multi-modal biomedical data, including text, images, and molecular structures. Regulatory pathways are evolving to accommodate AI-discovered or repurposed drugs, with health agencies developing frameworks for validation and transparency.